BRIEF-Bayer Strengthens Cardiovascular Portfolio With Cytokinetics' Aficamten In Japan

Reuters
19 Nov 2024

Nov 19 (Reuters) - Bayer AG :

* STRENGTHENS CARDIOVASCULAR PORTFOLIO WITH CYTOKINETICS' AFICAMTEN IN JAPAN

* EXCLUSIVE LICENSE AGREEMENT WITH CYTOKINETICS TO DEVELOP AND COMMERCIALIZE AFICAMTEN IN JAPAN

* CYTOKINETICS WILL RECEIVE APPROXIMATELY EUR 70 MILLION IN UPFRONT AND NEAR-TERM PAYMENTS

* IS ELIGIBLE TO RECEIVE UP TO EUR 490 MILLION IN COMMERCIAL MILESTONE PAYMENTS WITH TIERED ROYALTIES ON FUTURE SALES

* HIGHLY STRATEGIC FIT ADDING TO BAYER'S COMMERCIAL FOOTPRINT IN SPECIALTY CARDIOLOGY

Source text: Further company coverage:

((frankfurt.newsroom@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10